Bleeding diathesis and allogenic transfusion after complex heart surgery, such as heart valve surgery, may result in complications such as transfusion reaction, viral infection, postoperative infection, haemodynamic disturbance, prolonged stay in the intensive care unit and hospital, renal and respiratory failure and mortality. In this prospective, double-blind, randomized, placebo-controlled clinical trial, 90 patients were randomly divided into three groups: aprotinin, tranexamic acid and control. Chest-tube drainage, transfusion requirements and renal and neurological complications were evaluated. We found that chest-tube drainage during the first (P < 0.0001) and second 24 h (P = 0.001) after admission to the intensive care unit were significantly lower in the aprotinin group. The amounts of transfused packed red blood cells (P < 0.0001) and platelets (P = 0.02) were significantly lower in the aprotinin and tranexamic acid groups. The quantity of transfused fresh frozen plasma (P = 0.034) was significantly lower in the aprotinin group only. We did not find any neurological complications or renal failure in the three groups. Our data suggest that in valvular heart surgery, low-dose aprotinin is significantly better than tranexamic acid or a placebo for reduction of postoperative bleeding and allogenic transfusion, without increasing adverse outcomes.
INTRODUCTION
Bleeding is one of the most common complications after heart surgery, especially in complex procedures, such as valvular heart surgery [1] . There is a need to control bleeding diathesis after heart surgery. Some studies have reported that aprotinin use is associated with an increase in the risk for renal, myocardial and cerebral complications in coronary artery bypass graft surgery, and some of these studies have reported that aprotinin use is an independent predictor of 5-year mortality [2, 3] . There is an increase in the incidence of valvular heart surgery in developed and underdeveloped countries and insufficient knowledge concerning the effects of antifibrinolytic drugs on postoperative bleeding and the potential for renal, myocardial and cerebral complications. Our 3-year clinical experience of using low-dose aprotinin in valvular heart surgery provoked us to design this study, in which the effects of tranexamic acid and aprotinin on post-valvular heart surgery bleeding were evaluated.
MATERIALS AND METHODS
After obtaining scientific and ethical approval from the research committees of the Isfahan University of Medical Sciences and obtaining written informed consent from the patients, we conducted a non-sponsored, single-centre, prospective, doubleblind, randomized, placebo-controlled clinical trial in patients with normal renal function.
Inclusion criteria were as follows: (i) age >18 years; (ii) not pregnant; (iii) elective operation; (iv) absence of known or suspected allergy to aprotinin or tranexamic acid; (v) absence of previous sternotomy, pre-existing renal dysfunction (serum creatinine >1.36 mg/dl), preoperative coagulation defects [ prothrombin time (PT) >18 s or activated partial prothrombin time (aPTT) >50 s or platelet count <100 × 109/l], recent (<5 days) ingestion of acetylsalicylic acid, thrombolytic therapy (streptokinase, urokinase or tissue plasminogen activator <1 day preoperatively), anticoagulant therapy (heparin <4 h preoperatively or warfarin <3 days preoperatively), autologous predonation of blood, history of thrombotic events such as deep vein thrombosis, disseminated intravascular coagulation and cerebral thromboembolic accident in the previous 6 months, or unstable angina. Exclusion criteria were as follows: (i) pump time >120 min; and (ii) bleeding with a surgical source (identified at postoperative reoperation).
For this study, 90 patients were randomly divided into three groups (30 patients in each group) after arrival in the operating room and the establishment of standard monitoring techniques. For anticoagulation, we administered heparin sulfate 4 mg/kg intravenously until an activated clotting time of >460 s was achieved using a kaolin-based activator. To rule out hypersensitivity to aprotinin or tranexamic acid, a 1 ml test dose of the trial medications was given intravenously to all patients 10 min before administration of the initial loading dose.
In aprotinin group, after patient heparinization we infused 50 ml of normal saline intravenously over 20 min. Then, 1 000 000 kallikrein inhibition units (KIU) of aprotinin (Gedeon Richter) (100000 KIU per 10 ml) were added to the priming fluid. During the cardiopulmonary bypass (CPB), we infused 500 000 KIU of aprotinin in 50 ml of normal saline.
In the tranexamic acid group, after patient heparinization we infused 30 mg/kg tranexamic acid (Caspian Pharmaceutical Co.) intravenously in 50 ml of normal saline over 20 min. Then 100 ml normal saline was added to the priming fluid and tranexamic acid infusion was continued during CPB at 1 mg/kg in 50 ml of normal saline.
In the control group, after patient heparinization 50 ml of normal saline was administered intravenously over 20 min, and 100 ml of normal saline was added to the priming fluid. During CPB, we infused 50 ml of normal saline.
At the end of surgery, the heparin was neutralized by protamine sulfate (not >10% above baseline) and the plasma fibrin derivative product (FDP) concentration was checked.
Postoperatively, the amount of chest-tube drainage was evaluated in the first and second 24 h of intensive care unit (ICU) residency, and patients with <9 mg/dl haemoglobin received allogenic packed red blood cells. Fresh frozen plasma (FFP) was administered when the aPTT and PT were prolonged (>1.5 times control value) during active bleeding. A platelet count of <50 000/mm 3 or continuation of bleeding after FFP transfusion was an indication for platelet transfusion. Surgical re-exploration was considered if bleeding was >400 ml/h for 2 h, >300 ml/h for 3 h or >200 ml/h for 4 h, postoperatively.
The major parameters that we evaluated in this study were as follows: chest-tube drainage, the type and number of units of blood and blood products transfused, coagulation tests and haemoglobin/haematocrit and platelet count preoperatively, 6 and 24 h after ICU admission, neurological deficits (drowsiness, agitation, focal neurological deficit, convulsion and coma), renal failure and plasma FDP concentration at the end of surgery.
In addition, we assessed demographic items, the number of exchanged heart valves, the length of stay in the ICU bedridden and the hospital mortality. After discharge from the ICU, patients underwent echocardiographic evaluation.
Data were analysed by one-way analysis of variance (ANOVA), Duncan's test and the Kruskal-Wallis test using SPSS software .
RESULTS
There were no statistical differences between the demographic parameters in the three groups ( Table 1) .
The aPTT and international normalized ratio (INR) in the aprotinin and tranexamic acid groups were significantly lower compared with the control group 6 h after ICU admission. By 24 h after arrival in the ICU, PT and INR in in the aprotinin group were significantly lower than in the tranexamic acid and control groups, but there were no significant differences in aPTT values between the three groups ( Figs 1 and 2 and Table 2 ). The haemoglobin and haematocrit were significantly greater in the aprotinin group only at 24 h after ICU admission (Fig. 3 and Table 2 ).
Instead of temperature before CPB weaning and during bedridden ICU stay, temperature during CPB was lower in the control group (Table 1) .
There were no significant differences among the three groups in the mean arterial blood pressure changes after the administration of drugs.
Chest-tube drainage during the first 24 h after ICU admission was significantly greater in the control group, whereas during the second 24 h of ICU residency it was significantly lower in the aprotinin group (Tables 2 and 3 ).
The amount of transfused packed red blood cells was significantly lower in the aprotinin and tranexamic acid groups. The quantity of transfused FFP was significantly lower in the aprotinin group only. The requirement for platelets was significantly greater in the control group (Fig. 4 and Tables 2 and 4) . We did not find any evidence of neurological complications or renal failure in patients in any of the three groups.
DISCUSSION
Bleeding is one of the most common complications after cardiac surgery, especially valvular replacement surgery. In this study, we evaluated the influence of aprotinin and tranexamic acid on postoperative bleeding following heart valvular operations and patient requirements for allogenic blood and blood products. We found that low-dose aprotinin controlled postoperative bleeding and reduced requirements for allogenic blood products better than tranexamic acid, and both drugs were better than a placebo.
The influence of tranexamic acid (30 mg/kg) and low-dose aprotinin (500 000 KIU) on postoperative blood loss and transfusion requirements in primary mitral valve surgery were evaluated by Ait Houssa et al. in a retrospective study that found relatively different effects of the two fibrinolytic inhibitors, They suggested that a randomized and controlled clinical trial was needed in order to establish the superiority of one of the two products [4] . In a prospective, double-blind, randomized study, Dietrich et al. revealed that, regarding the rate of transfusion of red blood cells, aprotinin was better than tranexamic acid in patients undergoing coronary artery bypass graft, but there was no difference in patients receiving aortic valve replacement [5] . Woldow et al. evaluated the efficacy of low-dose aprotinin (2 million KIU pump prime volume only) and low-dose tranexamic acid (1000 mg pump prime volume) in 708 consecutive patients from two prospective registers undergoing elective cardiac procedures with CPB; they revealed that postoperative blood loss and transfusion requirements were significantly lower in patients treated with aprotinin rather than tranexamic acid [6] . Mengistu et al. evaluated the effects of aprotinin and tranexamic acid on platelets and postoperative blood loss in cardiac surgery and showed that platelet function measured by whole blood aggregation is better preserved by aprotinin compared with tranexamic acid and may be responsible for producing less bleeding in the first 24 h after a cardiopulmonary bypass [7] .
In the present prospective, randomized, double-blind, controlled clinical trial we found that after heart valve surgery, low-dose aprotinin could control bleeding diathesis and reduce requirements for allogenic transfusion better than tranexamic acid or placebo. In our study, there were no differences in blood platelet counts among the three groups; we did not measure platelet function.
In a meta-analysis, Brown et al. revealed that all antifibrinolytic agents (aprotinin, tranexamic acid and -aminocaproic acid) were effective in reducing blood loss and transfusion. There were no significant risks or benefits for mortality, stroke, myocardial infarction or renal failure; however, high-dose aprotinin was associated with a statistically significant risk of renal dysfunction [8] .
In an observational study of 4374 patients undergoing cardiac surgery, Mangano and associates reported that use of aprotinin was associated with a doubling of the risk of dialysis-dependent renal failure, as well as a 55% increase in the risk for heart failure and a 181% increase in the risk for stroke or encephalopathy [2] . Subsequently, they reported that use of aprotinin was an independent predictor of 5-year mortality [3] .
In our study, we did not find any neurological complications or renal failure in patients in any of the three groups. At the postoperative echocardiographic evaluation, we did not find any thrombotic complications in the three groups. No significant differences between three groups were observed for FDP concentration. Therefore, we hypothesize that aprotinin, together with other mechanisms, such as prevention of platelet dysfunction, leads to a reduction of postoperative bleeding and transfusion.
Our study was limited by the relatively small number of eligible patients, especially with regard to neurological and renal complications.
We conclude that for valvular heart surgery, low-dose aprotinin is more effective than tranexamic acid or a placebo and can reduce postoperative bleeding and the requirement for a transfusion of allogenic blood and blood products, without an increase in adverse effects. Values are presented as means ± SD. *P-value < 0.05.
